伊立替康与紫杉醇联合顺铂在宫颈癌新辅助化疗中的比较

Comparison of Irinotecan Combined With Cisplatin and Paclitaxel in Neoadjuvant Chemotherapy for Cervical Carcinoma

目的 观察伊立替康联合顺铂与紫杉醇联合顺铂在宫颈癌新辅助化疗中的临床效果,比较两种方法的应用价值。方法 在2015年4月-2016年4月将我院妇科收治的宫颈癌患者共46例作为试验对象。按治疗药物不同将其分为甲、乙两组,各23例,甲组患者给予伊立替康联合顺铂进行治疗,乙组患者给予紫杉醇联合顺铂药物治疗,对比两组患者用药后情况。结果 甲、乙两组治疗后临床疗效对比发现,甲组总有效率为95.65%,高于乙组的85.71%,甲组疗效更高,差异有统计学意义（P〈0.05）;对比治疗后不良反应发生率,甲组不良反应发生率为26.09%,乙组不良反应发生率为52.17%,相比之下,甲组用药安全性更高,差异有统计学意义（P〈0.05）。结论 经过对比后发现采用伊立替康联合顺铂,用药疗效与安全性都高于紫杉醇,可作为宫颈癌新辅助化疗中的首选药物。

Objective To investigate the clinical effects of irinotecan plus cisplatin and health paclitaxel and cisplatin in cervical cancer neoadjuvant chemotherapy, the comparative value of the two methods. Methods A total of 46 patients with cervical cancer who were admitted to our hospital from April 2015 to April 2016 in were selected as the experimental subjects. According to drug treatment will be different which is divided into two groups （A and B）, 23 cases in each. Group A patients received irinotecan and topotecan combined with cisplatin in the treatment, the patients of group B were given paclitaxel combined with cisplatin treatment and after treatment were compared between two groups. Results A, B two groups clinical curative effect comparison, the total efficiency of the first group was 95.65%, higher than that of group B 85.71%, group a higher curative effect, the difference was statistically significant （P〈0.05）, the incidence rate of adverse reaction after treatment were compared, the first division of adverse reactions occur rate was 26.09%. In group B, the adverse reactions occurrence rate was 52.17%, in contrast, division of drug safety was higher, the difference was statistically significant （P〈0.05）. Conclusion After comparison found that the use of irinotecan and topotecan combined with cisplatin, drug efficacy and safety are higher than that of paclitaxel, as neoadjuvant chemotherapy for cervical cancer drug of choice.